Anja Gesierich

Anja Gesierich

Auto-generated profile, based on publicly available information

Anja Gesierich

Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FIfor the ERIVANCE BCC Investigators
for the ERIVANCE BCC Investigators
ASAleksandar Sekulic
Aleksandar Sekulic
MMMichael R. Migden
Michael R. Migden
NBNicole Basset-Seguin
Nicole Basset-Seguin
Claus GarbeClaus Garbe
Claus Garbe
AHAxel Hauschild
Axel Hauschild
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review were 45% (mBCC) and 60% (laBCC). Herein, we present long-term safety and final investigator-assessed efficacy results in patients with mBCC or laBCC. One hundred four patients with measurable advanced BCC received oral vismodegib 150 mg once daily until disease progression or intolerable toxicity. The primary end point was IRF-assessed ORR. Secondary end points included ORR, duration of response (DOR), progression-free survival, overall survival (OS), and safety. At data cutoff (39 months after completion of accrual), 8 patients were receiving the study drug (69 patients in survival follow-up). Investigator-assessed ORR was 48.5% in the mBCC group (all partial responses) and 60.3% in the laBCC group (20 patients had complete response and 18 patients had partial response). ORRs were comparable across patient subgroups, including aggressive histologic subtypes (eg, infiltrative BCC). Median DOR was 14.8 months (mBCC) and 26.2 months (laBCC). Median OS was 33.4 months in the mBCC cohort and not estimable in the laBCC cohort. Adverse events remained consistent with clinical experience. Thirty-three deaths (31.7%) were reported; none were related to vismodegib. This long-term update of the ERIVANCE BCC trial demonstrated durability of response, efficacy across patient subgroups, and manageable long-term safety of vismodegib in patients with advanced BCC. This study was registered prospectively with Clinicaltrials.gov , number NCT00833417 on January 30, 2009.


10 August 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MHMarkus V Heppt
Markus V Heppt
Timo SiepmannTimo Siepmann
Timo Siepmann
JEJutta Engel
Jutta Engel
GSGabriele Schubert-Fritschle
Gabriele Schubert-Fritschle
RERenate Eckel
Renate Eckel
CBCarola Berking
Carola Berking
Hotspot mutations of the oncogenes BRAF and NRAS are the most common genetic alterations in cutaneous melanoma. Specific inhibitors of BRAF and MEK have shown significant survival benefits in large phase III trials. However, the prognostic significance of BRAF and NRAS mutations outside of clinical trials remains unclear. The mutational status of BRAF (exon 15) and NRAS (exon 2 and 3) was determined in melanoma samples of 217 patients with pyrosequencing and Sanger sequencing. The genotypes were correlated with clinical outcomes and pathologic features of the primary tumors. Time to disease progression was calculated with the cumulative incidence function. Survival analyses were performed with Kaplan-Meier estimates and Cox proportional hazards regression analysis. Relative survival was calculated with the Ederer-II method. Treatment with BRAF and MEK inhibitors and immune checkpoint blockade (ICB) was allowed. Mutations in BRAF and NRAS were identified in 40.1 and 24.4% of cases, respectively. Concurrent mutations in both genes were detected in further 2.3%. The remaining 33.2% were wild type for the investigated exons (WT). BRAF mutations were significantly associated with younger age at first diagnosis (p < 0.001) and truncal localization of the culprit primary (p = 0.002). The nodular subtype was most common in the NRAS cohort. In addition, NRAS-mutant melanoma patients showed a higher frequency of nodal relapse (p = 0.013) and development of metastatic disease (p = 0.021). The time to loco-regional nodal relapse was shortest in NRAS-mutant melanoma (p = 0.002). Presence of NRAS mutation was an independent risk factor for disease progression in multivariate analysis (HR 2.01; 95% CI 1.02 – 3.98). BRAF-mutant melanoma patients showed a tendency for better overall and relative survival. Genotype was not a consistent risk factor in multivariate analysis. Instead, positive sentinel lymph node status (HR 2.65; 95% CI 1.15 – 6.10) and treatment with ICB in stage IV disease (HR 0.17; 95% CI 0.06–0.48) were significant multivariate risk factors. NRAS-mutant tumors tended to behave more aggressively particularly in early stages of the disease in this high-risk melanoma population. Treatment with immune checkpoint blockade improved survival in stage IV disease in a real-world setting.

1 August 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
MHMarkus V Heppt
Markus V Heppt
ARAlexander Roesch
Alexander Roesch
BWBenjamin Weide
Benjamin Weide
Ralf GutzmerRalf Gutzmer
Ralf Gutzmer
FMFriedegund Meier
Friedegund Meier
CBCarola Berking
Carola Berking

1 February 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
SGSimone M. Goldinger
Simone M. Goldinger
KBKristina Buder-Bakhaya
Kristina Buder-Bakhaya
SLSerigne N. Lo
Serigne N. Lo
AFAndrea Forschner
Andrea Forschner
MMMeredith McKean
Meredith McKean
AMAlexander M. Menzies
Alexander M. Menzies

23 July 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
VHV. Haug
V. Haug
VBV. Behle
V. Behle
SBS. Benoit
S. Benoit
HKH. Kneitz
H. Kneitz
BSB. Schilling
B. Schilling
AGA. Gesierich
A. Gesierich